Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplied by Immunine binds to activated factor X on platelet surfaces, forming the intrinsic tenase complex. This complex accelerates the conversion of prothrombin to thrombin, leading to fibrin clot formation and effectively correcting the clotting defect caused by factor IX deficiency.

The dose of Immunine is individualized by the prescribing clinician based on the patient’s factor IX activity level, weight, severity of bleeding, and clinical response. Exact dosing regimens are determined by the treating physician and are not standardized in public information.

The safety of Immunine in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh the potential benefits against any unknown risks and consider alternative therapies if appropriate.

To order Immunine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Immunine is a plasma‑derived Factor IX concentrate, similar in activity to recombinant factor IX products. While recombinant forms avoid plasma‑derived pathogen risk, both provide comparable efficacy in correcting factor IX deficiency. Choice between them depends on physician preference, patient tolerance, and supply considerations.

Immunine must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

Immunine is supplied as a sterile solution for injection and is administered intravenously. The infusion rate and volume are determined by the prescribing clinician, and the product should be given using aseptic technique in a clinical setting.

Serious risks include the development of inhibitory antibodies against factor IX, severe allergic or anaphylactic reactions, thrombotic events, and the theoretical risk of transmission of blood‑borne pathogens despite rigorous donor screening and viral inactivation processes.

Immunine should be avoided in patients with known hypersensitivity to any component of the product, in those who have previously developed inhibitors to factor IX, or in individuals with uncontrolled active thrombosis. Clinical judgment is required for each case.